Description:BrightEdge, the innovation impact investment and venture capital arm of the American Cancer Society, plays a pivotal role in advancing cancer research and treatment. Through its donor-funded ACS Impact Venture Fund (AIVF), BrightEdge strategically invests in for-profit, early-stage companies that are at the forefront of developing groundbreaking therapeutics, diagnostics, devices, and technologies specifically designed to combat cancer. By channeling investments into these cutting-edge initiatives, BrightEdge actively supports the overarching mission of the American Cancer Society: to end cancer as it is known for everyone. Through this commitment to innovation and collaboration in the healthcare sector, BrightEdge strives to facilitate significant advancements in cancer care, ultimately aiming to create a world where cancer is no longer a formidable threat.